The diagnosis of PDAC typically involves a combination of clinical assessment, biopsy, imaging studies, and the evaluation of tumor biomarkers, including carbohydrate antigen 19‐9 (CA19‐9), carbohydrate antigen 242 (CA242), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), and K‐RAS gene mutations.295. Here, CEACAM5 is linked to neoplasm.